A scientist in AIRNA's research labs in Tübingen, Germany (Credit: AIRNA)

RNA edit­ing start­up launch­es with $30M based on Stan­ford and Uni­ver­si­ty of Tübin­gen re­search

The race to de­vel­op new ther­a­pies that pre­cise­ly ed­it short-lived RNA mol­e­cules in­stead of mak­ing ir­re­versible changes to DNA is heat­ing up. A new en­trant to the grow­ing field emerged from stealth Tues­day morn­ing with a $30 mil­lion ini­tial fi­nanc­ing round led by ARCH Ven­ture Part­ners to make RNA edit­ing ther­a­pies for both rare and com­mon dis­eases.

The start­up, called AIR­NA, was co-found­ed in 2021 by Thorsten Stafforst — a Uni­ver­si­ty of Tübin­gen bio­chemist whose work over the past decade helped spark in­ter­est in RNA edit­ing ther­a­pies — and Jin Bil­ly Li, a Stan­ford Uni­ver­si­ty bi­ol­o­gist who has stud­ied the en­zymes that pow­er RNA edit­ing in na­ture since 2006.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA